The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment. ...
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
India Today on MSN
Studied together, not competing: How twin brothers cracked clat 2026 with AIR 2, 8
Twin brothers Argh and Parv Jain have emerged as standout performers in CLAT 2026, clinching AIR 8 and AIR 2 in one of the ...
The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback